Particularly active antibodies as a barrier to SARS-CoV-2 24 August 2021

Link to article
cellules bronchiques humaines (bleues) infectées par le virus SARS-CoV-2

“Stained image of human bronchial cells (blue) infected with SARS-CoV-2 (orange). (c) Institut Pasteur. Image by Rémy Robinot, Mathieu Hubert, Vincent Michel, Olivier Schwartz and Lisa Chakrabarti, colors by Jean Marc Panaud”.

This work, in press in Science Translational Medicine and pre-published on Monday, December 7, 2020, on the Science Translational Medicine journal website, shows that the IgA antibody response plays a critical role in neutralizing the SARS-CoV-2 virus early and particularly effectively.

IgA antibodies play an essential role in protecting the body’s mucous membranes, particularly the respiratory tract. It was therefore logical to study this particular antibody response in patients infected with SARS-CoV-2. Researchers and clinicians affiliated with the CIMI Research Centre (Sorbonne University and Inserm) in collaboration with several clinical services of the APHP-Sorbonne University and teams from the Pasteur Institute, show that the IgA response plays a primordial role in neutralising the SARS-CoV-2 virus early and particularly effectively.

Somewhat surprisingly, IgA antibodies are often the first detectable virus-specific antibodies. This is an unusual profile, as immunological dogma dictates that the IgM response is dominant upon encountering an unknown pathogen. The virus-induced stimulation induces a very large expansion of young IgA antibody-secreting cells (plasmablasts) that circulate between the blood and the mucous membranes in which they are able to reside. However, this IgA antibody response is slowly declining, including in the saliva.

The teams in charge of this work show that in the first few weeks after infection, IgA antibodies do most of the work of neutralising the virus. The level of these antibodies rapidly decreases in the blood and becomes weakly detectable in most subjects 30 days after the onset of symptoms. However, these antibodies remain detectable and active in saliva for a longer period of time (up to 73 days after the onset of symptoms) although this level of local protection also appears to decline slowly. In a subgroup of patients with a mild ambulatory form, it is reported that approximately 6 months after counting, the saliva no longer exerts a neutralising effect on the virus. These preliminary results on saliva do not necessarily imply a lack of protection at the tissue level, especially in patients with a more severe form of the disease.

In conclusion, this work highlights the potent protective character of IgA. It raises the question of the possible role of secretory IgA in limiting virus transmission. It will therefore be interesting to evaluate to what extent the various vaccines that will soon be widely available could induce, or not, a systemic or even mucosal IgA response. If necessary, it could be envisaged to eventually include a local stimulation in our vaccine strategies, in the form of local nebulisations for example.


IgA dominates the early neutralizing antibody response to SARS-CoV-2 : D. Sterlin, A. Mathian, M. Miyara, A. Mohr, F. Anna, L. Claër, P. Quentric, J. Fadlallah, H. Devilliers, P. Ghillani, C. Gunn, R. Hockett, S. Mudumba, A. Guihot, C-E. Luyt, J. Mayaux, A. Beurton, S. Fourati, T. Bruel, O. Schwartz, J-M. Lacorte, H. Yssel, C. Parizot, K. Dorgham, P. Charneau, Z. Amoura, G. Gorochov. Science Translational Medicine, in press.